Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse

Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse

Background: The current standard of care for patients without sentinel node (SN) metastasis (i.e., stage I–II melanoma) is watchful waiting, while >40% of patients with stage IB–IIC will eventually present with disease recurrence or die as a result of melanoma. With the prospect of adjuvant thera...

Full description

Bibliographic Details
Main Authors: Evalyn E. A. P. Mulder, Iva Johansson, Dirk J. Grünhagen, Dennie Tempel, Barbara Rentroia-Pacheco, Jvalini T. Dwarkasing, Daniëlle Verver, Antien L. Mooyaart, Astrid A. M. van der Veldt, Marlies Wakkee, Tamar E. C. Nijsten, Cornelis Verhoef, Jan Mattsson, Lars Ny, Loes M. Hollestein, Roger Olofsson Bagge
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
primary cutaneous melanoma
clinicopathologic and gene expression model
risk stratification recurrence
Online Access:https://www.mdpi.com/2072-6694/14/12/2854

Internet

https://www.mdpi.com/2072-6694/14/12/2854

Similar Items